Evidence map›Paper›PMID 40736712›Full record

ArticleClinical and experimental medicine2025

Mechanism of USP11 regulated SIRT3/ROS in drug resistance of acute myeloid leukemia.

Pinwei Zhu, Hang Li, JinLi Ge, Zhencang Zhou, Dengke Chen, Qiang Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pinwei ZhuHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Hang LiHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China.
JinLi GeHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Zhencang ZhouHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Dengke ChenHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China.
Qiang LiHematology department, The First People's Hospital of Zunyi(The Third Affiliated Hospital of Zunyi Medical University), No. 98 Fenghuang North Road, Huichuan District, Zunyi, 563000, Guizhou, China. alcm405517@outlook.com.

Funding

the Science and Technology plan project in Zunyi No.HZ(2023)37
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) represents a highly heterogeneous group of hematological malignancies. This study aims to elucidate the protective role of USP11 in mediating drug resistance in AML. We observed elevated USP11 mRNA expression levels in AML patients. Notably, patients with high USP11 expression exhibited a lower overall survival rate compared to those with low USP11 expression. Single-cell analysis further revealed predominant expression of the USP11 gene in myeloid-derived suppressor cells within AML patients. Functionally, USP11 promoted cell growth and migration and enhanced chemotherapy-induced EdU incorporation in AML cells. Conversely, siUSP11 suppressed these effects, inhibiting cell growth and migration, as well as chemotherapy-induced EdU incorporation. In a mouse model, USP11 decreases the AML cells' sensitivity to chemotherapy in mice model by chemotherapy. Mechanistically, USP11 upregulated SIRT3 expression and enhanced reactive oxygen species (ROS) production in AML cells under chemotherapy. The proliferative effects of USP11 were attenuated by a SIRT3 inhibitor, confirming SIRT3 dependency. Additionally, methyltransferase-like 3 (METTL3) was found to enhance USP11 stability through N6-methyladenosine (m6A) RNA modification. Collectively, USP11 promotes chemotherapy resistance in AML cells via a SIRT3/ROS-dependent pathway, playing a pivotal role in treatment-induced drug resistance and emerging as a novel therapeutic target for AML.

Indexed as

Drug Resistance, NeoplasmLeukemia, Myeloid, AcuteReactive Oxygen SpeciesSirtuin 3Thiolester HydrolasesAnimalsCell Line, TumorCell MovementCell ProliferationFemaleHumansMaleMethyltransferasesMiceMethyltransferasesReactive Oxygen SpeciesSirtuin 3Thiolester HydrolasesUSP11 protein, humanAcute myeloid leukemiaDrug resistanceROSSIRT3USP11

Identifiers

PMID40736712
PMCPMC12310856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.